News

More people are being identified with hemophilia B across the eastern Mediterranean region, suggesting improvements in hemophilia diagnosis and reporting, according to a study analyzing 10 years of data from 14 countries in North Africa, the Middle East, and parts of Asia. Yet…

Blood tests can give different readings of factor VIII (FVIII) activity after treatment with Altuvoct (efanesoctocog alfa), marketed as Altuviiio in the U.S., a study found. The differences were greater when FVIII levels were low or several days had passed since an infusion, highlighting the need for careful interpretation;…

Bleeding that persists or restarts after dental procedures may be an important warning sign of previously undiagnosed mild hemophilia, a systematic review of published case reports suggests. Across seven reports involving eight people, delayed and persistent bleeding — in most cases after a tooth extraction — prompted further testing…

Artificial intelligence (AI) shows promise for helping doctors diagnose hemophilia, detect joint complications, and predict disease severity and other clinical outcomes, a review of published studies suggested. “However, methodological [diversity], limited external validation, and the scarcity of studies … remain important barriers to routine clinical implementation,” the researchers wrote.

Preventive treatment with low-dose Hemlibra (emicizumab-KXWH) significantly reduced bleeding and improved quality of life in young children with hemophilia A, regardless of inhibitor status, a real-world study in China found. But ultrasound scans showed signs of worsening joint health despite fewer clinically apparent bleeds, suggesting that lower doses may not…

More than half of people with hemophilia receiving prophylactic (preventive) factor replacement therapies at two treatment centers in Brazil did not collect enough medication to follow their prescribed treatment regimen, a real-world study has found. This gap between “prescription and practice” was evident even though Brazil provides universal,…

Hemophilia A patients rack up high hospital bills, driving costs for the healthcare system higher, a study from Canada showed. “This study confirms that even with improved [treatment to reduce bleeding], hemophilia A has a non-negligible impact on healthcare system costs,” researchers wrote in the study, “Population-Level Real-World…

A branch of the European Medicines Agency (EMA) has recommended that the experimental therapy denecimig be approved to treat adults and children with hemophilia A, with or without inhibitors. The recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) will be reviewed by the European…

Heavy periods in teenage girls should prompt further evaluation for an underlying bleeding disorder, such as hemophilia, rather than simply being considered a normal part of adolescence, according to a call to action from an international group of experts. Heavy menstrual bleeding, or HMB, can sometimes be the first — or…

A gene therapy that delivers instructions to produce a longer-lasting version of the clotting protein missing or deficient in hemophilia B may improve treatment effectiveness while maintaining a favorable safety profile, a study in mice suggests. Researchers in Belgium, working in a lab, combined the genetic instructions for a…